Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Fortress Biotech (FBIO) PT Raised to $13 at Roth/MKM
August 14, 2024 5:06 AM EDTRoth/MKM analyst Jason Whittes raised the price target on Fortress Biotech (NASDAQ: FBIO) to $13.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "FBIO reported 2Q24 revenues down 14.4% to $14.9 million vs. consensus of $14.8 million and our estimate of $14.0 million. EPS was ($0.73) vs.... More
